Evidence map›Paper›PMID 34671894›Full record

ArticleMolecular diversity2022

5-Oxo-hexahydroquinoline and 5-oxo-tetrahydrocyclopentapyridine derivatives as promising antiproliferative agents with potential apoptosis-inducing capacity.

Sara Ranjbar, Mehdi Khoshneviszadeh, Marjan Tavakkoli, Ramin Miri, Najmeh Edraki, Omidreza Firuzi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sara RanjbarPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mehdi KhoshneviszadehMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Marjan TavakkoliMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Ramin MiriMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Najmeh EdrakiMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. edrakin@sums.ac.ir.ORCID http://orcid.org/0000-0001-8306-2642
Omidreza FiruziMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. firuzio@sums.ac.ir.ORCID http://orcid.org/0000-0002-2248-5198
Shiraz University of Medical Sciences · IR

Funding

Vice-Chancellor for Research, Shiraz University of Medical Sciences 94-01-12-9472Vice-Chancellor for Research, Shiraz University of Medical Sciences 98-01-12-20483
6 · The paper itself

Abstract

Discovery of novel anticancer agents is of crucial importance to expand the therapeutic options for cancer patients. In this study, a series of 49 5-oxo-hexahydroquinoline and 5-oxo-tetrahydrocyclopentapyridine analogs, containing different pyridine alkyl carboxylates at C

Indexed as

Antineoplastic AgentsNeoplasmsQuinolinesApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular Docking SimulationStructure-Activity Relationship5-oxo-hexahydroquinolineAntineoplastic AgentsQuinolinesAnticancer activityBcl-2CytotoxicityDihydropyridineDrug designHematological malignanciesQuinoline

Identifiers

PMID34671894
OpenAlexW3207386490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.